ClinicalTrials.gg
RecruitingNCT07136792Updated Jan 15, 2026

A Study of Pegmolesatide of in Dialysis Chronic Kidney Disease (CKD) Patients With Anemia Treated With Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI)

An interventional study of Pegmolesatide 2mg SC and Pegmolesatide 4mg SC in Renal Anemia of Chronic Kidney Disease, sponsored by Guangdong Provincial People's Hospital. Recruiting at 24 sites in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-15.

Sponsored by Guangdong Provincial People's Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 116 studies in Anemia with a site in China — 32 open to participants now, 42 under way, 8 of them phase 3. Anemia · China.

Planned enrollment
61st of 98
96 · median 120
Started
2025
with 14 others
No phase
20 of 116
5 open now
Primary completion
2026-12
later than 19 of 41 live
Registered
107th of 116
by date

Among the 116 studies in Anemia with a site in China, this one is the 61st largest by planned enrollment of the 98 interventional ones that give a count, is one of 15 that started in 2025, is one of 20 with no phase, reaches primary completion later than 19 of the 41 other live ones, and was the 107th registered.

Anemia

1,812 studies on the registry are indexed under Anemia; 212 are open to participants now.

Browse Anemia studies →

Open to participants now

32 of the 116 studies in Anemia with a site in China are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 117 Anemia studies recruiting now, 66 (56%) set no upper age limit and 33 (28%) stop at 75 or younger; 32 take children under 18; 21 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 116 studies in Anemia with a site in China, or all of them as a file.
02

Study summary

For patients with renal anemia treated with hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), there is a clinical need of switching to long-acting and safe medications.

Pegmolesatide, a polyethylene glycol (PEG)-conjugated erythropoiesis-stimulating peptide, is a long-acting erythropoiesis-stimulating agent (ESA) with sustained activity. It was approved for marketing by the National Medical Products Administration (NMPA) in June 2023. Phase III clinical trials have demonstrated its efficacy and safety in dialysis patients with renal anemia who were previously treated with recombinant human erythropoietin (rHuEPO). However, there are currently no data regarding the efficacy and safety of switching from HIF-PHIs to pegmolesatide, and there is a lack of standard for the dose conversion.

This study is a multi-center, prospective, open-label, randomized parallel-controlled clinical trial, planning to enroll 96 patients.

All enrolled patients will receive 12 weeks of treatment and be followed up for 16 weeks.

Read the detailed description

For patients with renal anemia treated with HIF-PHIs, there is a clinical need of switching to long-acting and safe medications.

Pegmolesatide, a polyethylene glycol (PEG)-conjugated erythropoiesis-stimulating peptide, is a long-acting erythropoiesis-stimulating agent (ESA) with sustained activity. It was approved for marketing by the National Medical Products Administration (NMPA) in June 2023. Phase III clinical trials have demonstrated its efficacy and safety in dialysis patients with renal anemia who were previously treated with recombinant human erythropoietin (rHuEPO). However, there are currently no data regarding the efficacy and safety of switching from HIF-PHIs to pegmolesatide, and there is a lack of standard for the dose conversion.

This study is a multi-center, prospective, open-label, randomized parallel-controlled clinical trial, planning to enroll 96 patients.

Based on the weekly dose of Roxadustat before randomization, patients are divided into two cohorts: the low-dose Roxadustat cohort (weekly dose ≤210 mg) and the high-dose Roxadustat cohort (weekly dose >210 mg and ≤360 mg), with 48 patients in each cohort. Each cohort is stratified by hemoglobin (HB) level, with a 1:1 ratio for HB \<10.0 g/dl and HB ≥10.0 g/dl, meaning that there are 24 patients in both cohorts.

Within each cohort, patients are randomly assigned to 2 groups at a 1:1 ratio based on the initial treatment dose of pegmolesatide. Specifically, the patients in low-dose Roxadustat cohort are randomized into the Pegmolesatide initial dose 2 mg group or 4 mg group; the patients in high-dose Roxadustat cohort are randomized into the Pegmolesatide initial dose 4 mg group or 6 mg group, with 24 patients in each group entering the trial period. Pegmolesatide is administered subcutaneously once every 4 weeks, and the dosage is adjusted according to the drug's instructions for use. All enrolled patients will receive 12 weeks of treatment and be followed up for 16 weeks.

03

Conditions studied

  • Renal Anemia of Chronic Kidney Disease

Browse trials for

Keywords

  • Renal Anemia
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 18-75 years, regardless of gender;
  2. Body weight ≥ 45 kg, and (BMI) ≥ 18.5 kg/m²;
  3. Diagnosis of chronic renal failure, and having undergone a stable regimen of peritoneal dialysis or hemodialysis for at least 12 weeks prior to enrollment (with stable hemofiltration at a frequency of every 2 or 4 weeks if applicable). Stable dialysis frequency and no plans to change the dialysis modality during the trial;
  4. An up to standard dialysis adequacy testing result before randomization: spKt/V ≥ 1.2 for hemodialysis, Kt/V ≥ 1.7 for peritoneal dialysis;
  5. Roxadustat dose ≤ 360 mg/week within 4 weeks before randomization, with stable dose; [Stable dose is defined as: (the maximum weekly dose within 4 weeks before randomization - the average weekly dose within 4 weeks before randomization) ÷ the maximum weekly dose within 4 weeks before randomization ≤ 30%];
  6. Two pre-dialysis HB test values within 4 weeks before randomization of 8.0 - 12.0 g/dl, with an absolute difference between the two values ≤ 1.3 g/dl, and an interval of ≥ 7 days between the two HB tests;
  7. Serum ferritin level ≥ 100 μg/L and transferrin saturation (TAST) ≥ 20% at the time of testing before randomization, serum folate ≥ the lower limit of normal, and vitamin B12 ≥ the lower limit of normal;
  8. Understanding of the study procedures and voluntary signing of the written form.

Exclusion criteria

Exclusion Criteria:

  1. Known diseases, hematologic disorders (including congenital and acquired conditions such as thalassemia, Fanconi anemia, pure red cell aplasia, myelodysplastic syndrome, hemolytic anemia, and coagulation disorders), or other causes of anemia apart from CKD (such as gastrointestinal bleeding or hookworm disease).
  2. Confirmed diagnosis of acquired immunodeficiency syndrome (AIDS), syphilis, or tuberculosis and currently undergoing treatment.
  3. Known allergy to iron agents or polyethylene glycol molecules.
  4. Treatment history with ESAs in combination with HIF-PHIs drugs within 8 weeks prior to randomization.
  5. Underwent red blood cell or whole blood transfusion within 12 weeks prior to randomization.
  6. Poorly controlled blood pressure (uncontrolled hypertension is defined as: during the screening period, systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg in two or more blood pressure measurements, or although the blood pressure values are below the aforementioned criteria, the investigator deems it necessary to adjust antihypertensive medications).
  7. Active hepatitis or any of the following abnormal test results during the screening period ( ≥ 2 times the , AST ≥ 2 times the upper limit of normal, DBIL ≥ 2 times the upper limit of normal, serum albumin \< 2.5 g/dl).
  8. Participants judged by the investigator to have uncontrolled or symptomatic secondary hyperparathyroidism, or those with blood iPTH > 800 pg/mL during the screening period.
  9. C-reactive protein ≥ 30 mg/L during the screening period.
  10. Cardiac function assessed as Class III or IV during the screening period.
  11. Pregnant or breastfeeding women, or those planning to become pregnant during the study period.
  12. Participants who plan to undergo kidney transplantation during the trial period or have already been kidney donors, or those who plan to undergo elective surgery during the trial period.
  13. Participants deemed by the investigator to have any other factors that make them unsuitable for participation in this trial.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    Arm A1: Pegmolesatide 2mg SC

    All patients in low-dose Roxadustat cohort randomised into this group will receive pegmolesatide 2mg subcutaneously once every 4 weeks.

    Drug: Pegmolesatide 2mg SC

  • Experimental
    Arm A2: Pegmolesatide 4mg SC

    All patients in low-dose Roxadustat cohort randomised into this group will receive pegmolesatide 4mg subcutaneously once every 4 weeks.

    Drug: Pegmolesatide 4mg SC

  • Experimental
    Arm B1: Pegmolesatide 4mg SC

    All patients in high-dose Roxadustat cohort randomised into this group will receive pegmolesatide 4mg subcutaneously once every 4 weeks.

    Drug: Pegmolesatide 4mg SC

  • Experimental
    Arm B2: Pegmolesatide 6mg SC

    All patients in high-dose Roxadustat cohort randomised into this group will receive pegmolesatide 6mg subcutaneously once every 4 weeks.

    Drug: Pegmolesatide 6mg SC

Interventions

  • DrugPegmolesatide 2mg SC

    All patients will receive pegmolesatide 2mg subcutaneously once every 4 weeks.

  • DrugPegmolesatide 4mg SC

    All patients will receive pegmolesatide 4mg subcutaneously once every 4 weeks.

  • DrugPegmolesatide 4mg SC

    All patients will receive pegmolesatide 4mg subcutaneously once every 4 weeks.

  • DrugPegmolesatide 6mg SC

    All patients will receive pegmolesatide 6mg subcutaneously once every 4 weeks.

06

What researchers measure

Primary outcomes

  1. Change of mean HB level

    Change of mean HB level from baseline to 12 weeks and 16 weeks

    Time frame: from baseline to 12 weeks and 16 weeks

Secondary outcomes

  1. Change of mean HB level

    Change in mean HB levels from baseline to 12 weeks and 16 weeks, stratified by different baseline HB levels

    Time frame: from baseline to 12 weeks and 16 weeks

  2. Changes in red blood cell count

    Changes in red blood cell count from baseline to each follow-up

    Time frame: from baseline to 4 weeks, 8 weeks, 12 weeks, 16 weeks

  3. Median time to the first HB value reaching 10.0-12.0 g/dl

    Median time to the first HB value reaching 10.0-12.0 g/dl

    Time frame: From baseline to 4 weeks, 8 weeks,12 weeks and 16 weeks

  4. Proportion of patients with HB 10.0-12.0 g/dl

    Proportion of patients with HB 10.0-12.0 g/dl at each follow-up

    Time frame: from baseline to 4 weeks, 8 weeks,12 weeks and 16 weeks

  5. Proportion of patients with HB 11.0-13.0 g/dl

    Proportion of patients with HB11.0-13.0 g/dl at each follow-up

    Time frame: from baseline to 4 weeks, 8 weeks, 12 weeks and 16 weeks

  6. Average drug dose at each follow-up

    Time frame: From baseline to 4 weeks, 8 weeks,12 weeks and 16 weeks

  7. Adverse Events

    Safety of therapy by Investigator.

    Time frame: From the start of study drug to 30 days after the last dose of study drug

Other outcomes

  1. The Maximum Plasma Concentration

    The Maximum Plasma Concentration of Pegmolesatide

    Time frame: from the start of study drug to to 48 hours, 72 hours and 96 hours

07

Study locations

1 of 24 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Dec 2026, 15 months after the start.

Of 165 non-industry interventional studies with no phase under Anemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 30. This study's planned 15 months is below that.

Counting every sponsor, half of 179 studies reached it within 17 months; a quarter within 7 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2025
First posted
Aug 22, 2025
StartActual
Sep 8, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Jan 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07136792
Responsible party
XueQing Yu (professor, Guangdong Provincial People's Hospital) — Principal investigator
First posted
Aug 22, 2025
Start date
Sep 8, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jan 15, 2026

Study contacts

Xueqing Yu
Contact
yuxueqing@gdph.org.cn
+86-20-83827812
Zhiming ye
Contact
yezhiming@gdph.org.cn
138 2616 1678
Xueqing Yu
study chair · Guangdong Provincial People's Hospital
Zhiming Ye
study director · Guangdong Provincial People's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion